Price
No data yet.
Social Signal Score
Revenue
$151.04M+410.67%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Serge Saxonov
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 1,178
- Beta
- 2.04
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- 22.09
Financials
Revenue
$151.04M+410.7%Net Income
$-17.93MEBITDA
$-18.64MFree Cash Flow
$15.39MEPS (diluted)
$-0.14Shares Outstanding (diluted)
129.98M+901.0%Operating Expenses
$135.45MCash & Debt
$552.03MRevenue by Segment (annual)
$1.24BQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $642.82M | $-43.54M | $-0.35 |
| 2024 | $610.78M | $-182.63M | $-1.52 |
| 2023 | $618.73M | $-255.10M | $-2.18 |
| 2022 | $516.41M | $-166.00M | $-1.46 |
| 2021 | $490.49M | $-58.22M | $-0.53 |
| 2020 | $298.85M | $-542.73M | $-5.37 |
| 2019 | $245.89M | $-31.25M | $-0.80 |
| 2018 | $146.31M | $-112.48M | $-8.40 |
| 2017 | $71.08M | $-18.76M | $-1.62 |
Valuation
TXGhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
105-19.23%Social Signal Score
Mentions (2)
- Newszacks.com·1d ago·Neutral
10x Genomics Rallies 84% in 3 Months: Is There More Upside Ahead? TXG's 84% rally is backed by consumables growth, Atera demand and higher guidance, but weak instruments and valuation raise the bar.
View source ↗ - Newszacks.com·4d ago·Positive
TXG Stock Down Despite Patent Verdict Win Against Parse Biosciences 10x Genomics wins a $4.8M patent verdict against Parse, strengthening its IP position as it seeks added damages and a U.S. injunction.
View source ↗
Earnings
Thu, Nov 5(in 2 months)
Consensus estimate $-0.27 per share
Typical surprise +31.6% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$-0.14 vs $-0.24beat
- Thu, May 7$-0.10 vs $-0.29beat
- Thu, Feb 12$-0.13 vs $-0.19beat
- Thu, Nov 6$-0.22 vs $-0.07miss
- Thu, Aug 7$0.28 vs $-0.35beat
- Thu, May 8$-0.36 vs $-0.45beat
Estimates and results for TXG via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by TXG officers and directors.
- Bought
- $446k
- Sold
- $11.8m
1 trade
51 trades
- Saxonov Sergesold
- Saxonov Sergesold
- Saxonov Sergesold
- Saxonov Sergesold
- Taich Adamsold
- Hindson Benjamin J.sold
- Suliman Shehnaazsold
- Suliman Shehnaazsold
48 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.